3 documents found, page 1 of 1
Extraskeletal osteosarcoma: A European Musculoskeletal Oncology Society study o...
Longhi, A; Bielack, SS; Grimer, R; Whelan, J; Windhager, R; Leithner, A; Gronchi, A; Biau, D; Jutte, P; Krieg, AH; Klenke, FM; Grignani, G; Donati, DMPURPOSE: Prognosis of extraskeletal osteosarcoma (ESOS) is reported to be poorer than that of skeletal osteosarcoma. This multicenter retrospective study aimed to evaluate factors influencing ESOS prognosis. PATIENTS AND METHODS: Members of the European Musculoskeletal Oncology Society (EMSOS) submitted institutional data on patients with ESOS. RESULTS: Data from 274 patients treated from 1981 to 2014 were coll...
Mesenchymal chondrosarcoma: prognostic factors and outcome in 113 patients. A E...
Frezza, AM; Cesari, M; Baumhoer, D; Biau, D; Bielack, S; Campanacci, DA; Casanova, J; Esler, C; Ferrari, S; Funovics, PT; Gerrand, C; Grimer, RBACKGROUND: Mesenchymal chondrosarcoma (MCS) is a distinct, very rare sarcoma with little evidence supporting treatment recommendations. PATIENTS AND METHODS: Specialist centres collaborated to report prognostic factors and outcome for 113 patients. RESULTS: Median age was 30 years (range: 11-80), male/female ratio 1.1. Primary sites were extremities (40%), trunk (47%) and head and neck (13%), 41 arising primar...
Current and future chemotherapy for chagas disease
Gaspar, L; Moraes, C; Freitas-Junior, L; Ferrari, S; Costantino, L; Costi, M; Coron, R; Smith, TK; Siqueira-Neto, J; McKerrow, J; Cordeiro-da-Silva, AHuman American trypanosomiasis, commonly called Chagas disease, is one of the most neglected illnesses in the world and remains one of the most prevalent chronic infectious diseases of Latin America with thousands of new cases every year. The only treatments available have been introduced five decades ago. They have serious, undesirable side effects and disputed benefits in the chronic stage of the disease - a ...